Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-UMIN000059294) titled 'A biomarker study associated with a randomized, prospective phase II trial comparing the efficacy and safety of mFOLFOX6 plus cetuximab (q2w) versus mFOLFOX6 plus bevacizumab as first-line treatment for unresectable right-sided colon cancer with RAS/BRAF wild-type' on Oct. 6.
Study Type: Observational
Study Design:
Not selected Not selected
Primary Sponsor: JR Sendai Hospital
Condition:
unresectable colon cancer
Recruitment Status: Recruiting
Phase: Not selected
Date of First Enrollment: 2025/05/31
Target Sample Size: 110
Countries of Recruitment:
Japan
To know more, visit https://center6.umin.ac...